194 related articles for article (PubMed ID: 34240274)
1. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract][Full Text] [Related]
2. Mutations in epigenetic regulator
Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Metabolic Genes in Breast Cancer Based on Multi-Omics Data.
Hua Y; Gao L; Li X
Pathol Oncol Res; 2021; 27():1609789. PubMed ID: 34408553
[No Abstract] [Full Text] [Related]
4. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
5. Mutations in
Liu D; Benzaquen J; Morris LGT; Ilié M; Hofman P
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681795
[TBL] [Abstract][Full Text] [Related]
6. KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.
Xie K; Peng Y; Zhong W; Liu X
Front Biosci (Landmark Ed); 2022 Mar; 27(3):103. PubMed ID: 35345335
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer.
Li Y; Yang X; Geng C; Liu Y; Tang T; Zhang L; Liu F; Zhang M; Hao J; Ma L
Front Immunol; 2024; 15():1390261. PubMed ID: 38726001
[TBL] [Abstract][Full Text] [Related]
9. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
[TBL] [Abstract][Full Text] [Related]
10. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients.
Huang Y; Liu J; Zhu X
Digit Health; 2022; 8():20552076221133699. PubMed ID: 36312851
[TBL] [Abstract][Full Text] [Related]
11. Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.
Sato K; Akimoto K
Clin Breast Cancer; 2017 Jun; 17(3):e135-e142. PubMed ID: 27986439
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer.
Acun T; Senses KM
Breast Cancer; 2020 May; 27(3):483-489. PubMed ID: 31902119
[TBL] [Abstract][Full Text] [Related]
13. Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer.
Simigdala N; Chalari A; Sklirou AD; Chavdoula E; Papafotiou G; Melissa P; Kafalidou A; Paschalidis N; Pateras IS; Athanasiadis E; Konstantopoulos D; Trougakos IP; Klinakis A
Cell Mol Life Sci; 2023 Mar; 80(4):100. PubMed ID: 36933062
[TBL] [Abstract][Full Text] [Related]
14. PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.
Zhang M; Zhang J
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729618
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
16. Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Wahabi K; Perwez A; Kamarudheen S; Bhat ZI; Mehta A; Rizvi MMA
BMC Cancer; 2019 Aug; 19(1):820. PubMed ID: 31429726
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
18. Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer.
Lian J; Xu C; Chen X; Huang S; Wu D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1627-1640. PubMed ID: 35322299
[TBL] [Abstract][Full Text] [Related]
19. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
20. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
Zhang L; Liu Z; Zhu J
Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
